Key result
AF ablation lowers long-term mortality and improves quality of life compared to AADs.
Why the study?
Debate persists regarding the most suitable option for rhythm control in AF, as prior studies have largely focused on short-term outcomes.
Does ablation improve long-term mortality, hospitalization, and quality of life compared to antiarrhythmic drugs in patients with atrial fibrillation?
Systematic Review
Does ablation improve long-term mortality, hospitalization, and quality of life compared to antiarrhythmic drugs in patients with atrial fibrillation?
Ablation appears superior to antiarrhythmic drugs for improving long-term mortality and quality of life in patients with atrial fibrillation.
Answers are grounded in this paper and cite their sources.
May support ablation preference over antiarrhythmic drugs for AF survival and QoL; extends low-certainty evidence from 15 studies.
Atrial fibrillation (AF) is a prevalent problem worldwide and a common cause of hospitalization, poor quality of life, and increased mortality. Although several treatments are used, the use of ablation and antiarrhythmic drug therapy has increased in the past decade. However, debate continues on the most suitable option for heart rhythm control in patients. Previous studies have largely focused on short-term outcome effects of these treatments. This systematic review aims to determine the effect of ablation compared to antiarrhythmic drugs for AF on long-term patient and health service outcomes of mortality, hospitalization, and quality of life. Three databases were systematically searched-studies were included if they reported long-term outcomes of more than 12 months comparing the 2 treatments. Title and abstract screening and subsequent full-text screening was done by 2 reviewers. Data were extracted from the final studies identified. The details of the search were recorded according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses report. A total of 2224 records were identified. After removing duplicates and screening the titles and abstracts, 68 records required full-text screening. Finally, 12 papers were included in the analysis. Eight studies reported mortality indicating ablation was superior, 2 studies reported hospitalization with opposing outcomes, and 5 quality of life studies indicating ablation was a better treatment. In studies assessing long-term outcomes, beyond 12 months, following ablation or rhythm control drugs for AF, most found a lower risk of death and greater improvement in quality of life in the ablation group.
No takes yet. Share an insight, caveat, or question.
Kularatna et al. (2022) conducted a systematic review in Atrial fibrillation. Ablation vs. Antiarrhythmic drugs was evaluated on Mortality, hospitalization, and quality of life. Ablation for atrial fibrillation demonstrated superior long-term (>12 months) mortality in 8 studies and better quality of life in 5 studies compared to antiarrhythmic drugs.
Synapse has enriched 10 related papers. Consider them for comparative context: